Sema4 to Acquire GeneDx, Strengthening its Market-Leading AI-Driven Genomic and Clinical Data Platform Business combination projected to deliver $350 million in pro forma 2022 revenue $200 million private placement from leading growth and life sciences investors, including Pfizer, will fortify...

Sema4 Announces Preliminary Revenue for the Fourth Quarter and Fiscal Year 2021 STAMFORD, Conn., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced preliminary revenue (unaudited) for the...

Sema4 to Participate at the 40th Annual J.P. Morgan Healthcare Conference in January STAMFORD, Conn., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced that Eric Schadt, PhD, Founder and...

Sema4 Reports Third Quarter 2021 Financial Results and Business Highlights 36% increase in test volume (excluding COVID-19 tests) compared to the same period last year 17% growth in revenue (excluding COVID-19 tests) compared to the same period last year ...

Sema4 and Mount Sinai use Machine Learning to Improve Postpartum Hemorrhage Risk Prediction STAMFORD, Conn., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ: SMFR), an AI-driven genomic and clinical data intelligence platform company, recently published two studies demonstrating the...